IP Library Granted Patent US 9,174,916
Granted Patent B2
US 9,174,916 · App. 13/769,644 · Granted Nov 3, 2015

Compounds and uses thereof for treating inflammation and modulating immune responses

Inventors: Allan Sy Lau (Hong Kong, CN); Lai Hung Cindy Yang (Hong Kong, CN); Chi Chung Stanley Chik (Hong Kong, CN); Chun Bong James Li (Hong Kong, CN)
Assignees: VERSITECH LIMITED; BAGI RESEARCH LIMITED
C07C59/64C07C69/734A61K31/235
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,174,916
App. No.
13/769,644
Granted
Nov 3, 2015
Kind
B2
Abstract

The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Claims (20)

1. A compound having the following formula:

wherein

R 1 is alkyl;

R 2 is alkyl;

R 3 , R 4 , and R 5 are independently —H, acyl, halo, haloalkyl, amino, alkylamino, hydroxyl, alkyl, hydroxylalkyl, or —COOH;

R 6 is —O or —NH;

R 7 is —H, alkyl, alkoxy, hydroxylalkyl, hydroxyl, or halo;

R 8 , R 9 , and R 12 are independently —H, acyl, halo, amino, alkylamino, hydroxyl, alkyl, hydroxylalkyl, or —COOH;

R 10 is H or alkyl; and

R 11 is H.

2. The compound, according to claim 1 , wherein R 3 is H, and R 4 is H.

3. The compound, according to claim 1 , wherein R 1 is a methyl group.

4. The compound, according to claim 1 , wherein the compound modulates immune activity in a mammal.

5. The compound, according to claim 1 , wherein the compound has inflammatory activity.

6. The compound, according to claim 1 , wherein the compound inhibits induction of TNF-α.

7. The compound, according to claim 6 , wherein the compound inhibits LPS-induced TNF-α production by at least 50%.

8. A pharmaceutical composition comprising an anti-inflammatory compound of claim 1

wherein the composition further comprises a pharmaceutically-acceptable carrier.

9. The composition, according to claim 8 , wherein the anti-inflammatory compound is a non-steroid anti-inflammatory drug (NSAID).

10. The composition, according to claim 9 , wherein the NSAID is selected from the group consisting of: aspirin, ibuprofen, and indomethacin.

Assignments (1)
CHANGE OF NAME Recorded Aug 25, 2014
From: PURAPHARM COMPANY LIMITED
To: BAGI RESEARCH LIMITED
Reel/Frame 033602/0363 →
Continuity (3)
Continuation 12647843 · Dec 28, 2009
Provisional Application 61143925 · Jan 12, 2009
Related Publication 20140255450A1 · Sep 11, 2014